ReviewJournal of clinical medicine2023
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Predictors of Mortality inPathogens (Basel, Switzerland) · 2026Review
- Surgical Site Infections and Antimicrobial Resistance: Six Years of Data from a Western Romanian Hospital.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- From computational screening toFrontiers in microbiology · 2026Article
- Potential of Eugenia brejoensis (Mazine) Essential Oil in Combating Multidrug-Resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa.Chemistry & biodiversity · 2026Article
- Promising Prodiginins Biological Activities.Chemistry & biodiversity · 2025Review
- Comparison of factors contributing to drug resistance and infection severity in Pseudomonas aeruginosa isolates among COVID-19 and non-COVID-19 patients.Molecular biology reports · 2025Article
- Development and evaluation of new nanoformulated thiolactone derivatives for enhanced disruption of pseudomonal biofilms.RSC advances · 2025Article
- Article
- The 1.3 Å resolution structure of the truncated group Ia type IV pilin from Pseudomonas aeruginosa strain P1.Acta crystallographica. Section D, Structural biology · 2024Article
- Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2024Article
- Article
- Deciphering the impact of microbial interactions on COPD exacerbation: An in-depth analysis of the lung microbiome.Heliyon · 2024Article
- Advances in Development of Novel Therapeutic Strategies against Multi-Drug ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Incidence of Carbapenem-Resistant Gram-Negative Bacterial Infections in Critically Ill Patients with COVID-19 as Compared to Non-COVID-19 Patients: A Prospective Case-Control Study.Critical care research and practice · 2024Article
- Antimicrobial resistance ofFrontiers in microbiology · 2024Review
- Article
- Evaluation of Blood Cultures from SARS-CoV-2-Positive and Negative Adult Patients.Healthcare (Basel, Switzerland) · 2023Article
- Relationship between COVID-19 and ICU-Acquired Bloodstream Infections Related to Multidrug-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial co-infections increase the severity of respiratory viral infections and are frequent causes of mortality in COVID-19 infected subjects. During the COVID-19 period, especially at the beginning of the pandemic, an inappropriate use of broad-spectrum antibiotic treatments has been frequently described, mainly due to prolonged hospitalization, especially in intensive care unit departments, and the use of immune-suppressive treatments as steroids. This misuse has finally led to the occurrence of infections by multi-drug resistant (MDR) bacteria in hospitalized COVID-19 patients. Although different reports assessed the prevalence of Gram-negative infections in COVID-19 infected patients, scarce data are currently available on bloodstream infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.